Membranoproliferative glomerulonephritis screening

Membranoproliferative glomerulonephritis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Membranoproliferative glomerulonephritis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Membranoproliferative glomerulonephritis screening On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Membranoproliferative glomerulonephritis screening All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Membranoproliferative glomerulonephritis screening
CDC on Membranoproliferative glomerulonephritis screening
Membranoproliferative glomerulonephritis screening in the news
Blogs on Membranoproliferative glomerulonephritis screening
Directions to Hospitals Treating Membranoproliferative glomerulonephritis
Risk calculators and risk factors for Membranoproliferative glomerulonephritis screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Jogeet Singh Sekhon, M.D. [2]

Overview

The entity, MPGN is a pathological definition, though it has some laboratory findings to guide to this diagnosis. Till now there is not specific screening protocols for MPGN, although it can diagnosed in the early stages by checking the proportion of urine protein to serum creatinine and 24 hour urine protein.